1. Academic Validation
  2. Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin

Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin

  • J Med Chem. 2020 May 14;63(9):4685-4700. doi: 10.1021/acs.jmedchem.9b02097.
Pan Huang 1 Xiangyang Le 2 Fei Huang 3 Jie Yang 1 Haofeng Yang 1 Junlong Ma 4 Gaoyun Hu 1 Qianbin Li 1 Zhuo Chen 1
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China.
  • 2 Department of Pharmacy, Yiyang Central Hospital, Yiyang 413000, Hunan, China.
  • 3 Center for Medical Experiments, Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China.
  • 4 Department of Good Clinical Practice, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.
Abstract

Apcin is one of the few compounds that have been previously reported as a Cdc20 specific inhibitor, although Cdc20 is a very promising drug target. We reported here the design, synthesis, and biological evaluations of 2,2,2-trichloro-1-aryl carbamate derivatives as Cdc20 inhibitors. Among these derivatives, compound 9f was much more efficient than the positive compound apcin in inhibiting Cancer cell growth, but it had approximately the same binding affinity with apcin in SPR assays. It is possible that another mechanism of action might exist. Further evidence demonstrated that compound 9f also inhibited tubulin polymerization, disorganized the microtubule network, and blocked the cell cycle at the M phase with changes in the expression of cyclins. Thus, it induced Apoptosis through the activation of Caspase-3 and PARP. In addition, compound 9f inhibited cell migration and invasion in a concentration-dependent manner. These results provide guidance for developing the current series as potential new Anticancer therapeutics.

Figures